Engflag

Cyra LS

Quick links to important sections

Cyra LS

Cyra LS_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cyra LS

Property Description
Active Ingredients Levosulpiride and Rabeprazole
Form Oral Tablet (Fixed-dose, Sustained-release/Enteric-coated)
Pharmacological Class Combination of a Proton-Pump Inhibitor (PPI) and a Prokinetic Agent
General Purpose Managing symptoms related to excessive stomach acid and impaired digestive motility
Origin Synthetic

Cyra LS is a prescription-only, synthetic fixed-dose combination drug intended for oral use, defined by its specialized composition that addresses issues related to both stomach acid and digestive tract movement. It is structurally classified within the Gastro Intestinal Tract Category of medicines. This combination is recognized for providing comprehensive relief in patients experiencing chronic acid-related discomfort.

What Type of Medicine is Cyra LS? (Identity and Classification)

Cyra LS is classified as a combination product because it integrates two different active ingredients into a single preparation, typically as an oral tablet. This fixed-dose format is frequently presented as an enteric-coated, sustained-release (SR) formulation. The enteric coating is a specialized mechanism that ensures the medication passes through the stomach without being prematurely degraded by acid, allowing the active ingredients to be absorbed effectively in the small intestine. This specific delivery system is a key differentiating feature, designed to optimize the sequential action of the dual components for sustained effect.

The Dual Composition: Levosulpiride and Rabeprazole (Composition and Class)

The core composition of Cyra LS features two key synthetic active substances: Rabeprazole sodium and Levosulpiride, each belonging to a distinct pharmacological class. Rabeprazole is categorized as a member of the Proton-Pump Inhibitor (PPI) class, which is recognized for its antisecretory mechanism. Concurrently, Levosulpiride is a substituted benzamide derivative that functions as a prokinetic agent. The combination of these two distinct pharmacological actions is a recognized method for addressing complex upper gastrointestinal issues. The use of anti-secretory agents alongside motility enhancers is a strategy to improve the function and comfort of the upper digestive tract.

Core Function: Anti-Acid and Motility Enhancement (General Purpose)

The general purpose of Cyra LS is to address two separate physiological factors contributing to digestive discomfort through a simultaneous dual mechanism of action. The Rabeprazole component achieves gastric acid suppression by limiting acid production, thereby protecting sensitive digestive linings from chemical irritation. The Levosulpiride component enhances gastrointestinal motility, which helps the stomach and intestines efficiently clear their contents and reduces the likelihood of digestive fluid backing up. This integrated action provides a foundational approach in the management of symptoms, such as persistent acidity and heartburn, that arise from both excessive acid and poor movement in the upper digestive tract. The prokinetic agent, Levosulpiride, is characterized by its action on the digestive system, which helps food move along more smoothly.

Regulatory References

  1. Enteric Coated Tablets

What side effects are possible with Cyra LS?

Possible Side Effects and Safety Information

The official safety profile for the Levosulpiride/Rabeprazole combination (Cyra LS) is established by government regulatory agencies, detailing potential adverse reactions and safety characteristics of its two components. Adverse reactions are formally categorized by frequency and grouped by the affected organ system, known as System-Organ Classes.

Frequency-Classified Adverse Reactions

The occurrence of side effects is officially documented using standard regulatory terminology:

  • Common Reactions (ge 1/100 to < 1/10): This category includes headache, diarrhea, nausea, abdominal pain, and flatulence, primarily associated with the Rabeprazole component. For Levosulpiride, galactorrhea and menstrual disorders may be documented as common in certain regions.
  • Uncommon Reactions (ge 1/1,000 to < 1/100): Examples include insomnia, dizziness, rash, and myalgia (muscle pain).
  • Reactions of Unknown Frequency: Events such as hyperprolactinemia (elevated prolactin levels) and extrapyramidal symptoms (involuntary movements) are documented for the Levosulpiride component, though without a defined frequency in all official labels.

Serious Reactions and Safety Contexts

The regulatory profile documents rare but clinically significant adverse reactions and specific safety constraints:

  • Serious Adverse Reactions: The Rabeprazole component is associated with the potential for Acute Interstitial Nephritis and severe skin reactions, such as Stevens-Johnson Syndrome. The Levosulpiride component carries a documented risk for Neuroleptic Malignant Syndrome (NMS).
  • Exposure-Related Patterns: Long-term use of the Rabeprazole component is associated with specific safety notes, including the potential for vitamin B12 deficiency and an increased risk of bone fractures in older adults.
  • Safety Restrictions: Use of Levosulpiride is generally constrained in individuals with conditions such as pheochromocytoma. Furthermore, caution is noted in patients with severe hepatic impairment, as clearance may be affected.

Overdose and Emergency Response

Overdose and when to seek help

Overexposure to Cyra LS is documented in regulatory sources primarily due to the potential toxicity of the Levosulpiride component. The officially recognized manifestations of overdose often involve the central nervous system, including drowsiness, tremors, confusion, and acute movement disorders known as extrapyramidal symptoms.

Overdose carries the potential for life-threatening outcomes. Of highest concern are severe neurological events such as Convulsions/Seizures and the development of Neuroleptic Malignant Syndrome (NMS). The profile also lists risks of critical cardiac arrhythmias, including QT prolongation, Ventricular Fibrillation, and Cardiac Arrest.

Emergency Response

The official guidance mandates that patients or caregivers seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the person is unconscious, has a seizure, or is experiencing trouble breathing. This urgency is driven by the severe neurological and cardiac risks.

Regulatory documents confirm that no specific antidote is known for this overdose profile. Consequently, clinical management is limited to providing symptomatic and supportive treatment. Hospital monitoring is required for continuous observation, particularly cardiac monitoring, to manage the documented risk of severe rhythm disturbances.

Therapeutic Uses of Cyra LS

What Cyra LS treats: main uses and benefits

This medicine is considered relevant for easing symptomatic discomfort associated with several digestive health conditions. It provides supportive relief in conditions characterized by periods of heightened symptoms, such as Gastroesophageal Reflux Disease (GERD). Its application is intended for the management of symptomatic GERD and related digestive disorders.

Cyra LS is applied across domains where additional symptomatic support is needed for managing symptoms that interfere with daily functioning, including discomfort related to peptic or duodenal ulcers and symptoms associated with Irritable Bowel Syndrome (IBS). It is often used during phases when symptoms become more noticeable, such as sudden heartburn, abdominal pain, or uncomfortable bloating.

This medicine helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.

Quick Fact: Targeted for Acid Reflux and Digestive Discomfort

“It offers symptomatic relief that helps patients cope more steadily with difficult episodes, supporting functional stability.”

Eligibility and Restrictions for Use

The official eligibility for Cyra LS (Levosulpiride and Rabeprazole) is defined by strict regulatory criteria tied to both its components. Only adults without listed contraindications are permitted use, though older adults may be used with caution.

Category Eligibility Classification
Contraindicated Populations Patients with known hypersensitivity to the drug or any component; those with Phaeochromocytoma; those with Prolactin-dependent tumors or a history of Breast Cancer; or patients with a history of Epilepsy or Mania.
Physical Contraindications Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation (due to the prokinetic component).
Age-Related Rule Children and Adolescents are not recommended for use, as safety and efficacy are not established in the pediatric population.
Organ & Reproductive Status Use is avoided in Severe Hepatic Impairment and contraindicated during Pregnancy and Lactation (breastfeeding).

The medicine is subject to regulatory restrictions due to the potential for the prokinetic agent to exacerbate existing neurological and physical risks. These classifications strictly define the population for whom the medicine is deemed safe and effective under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication has documented interactions with several drug classes and specific medicinal products. Certain combinations may be contraindicated or require close monitoring due to increased risk of serious adverse effects or altered drug efficacy.

Interacting Product Category Clinical Relevance & Mechanism
Anticoagulants (e.g., Warfarin) Concomitant use increases the International Normalized Ratio (INR) and prothrombin time, which can lead to abnormal bleeding, hemorrhage, and death.
Immunosuppressants (e.g., Cyclosporine) Inhibits the metabolism of cyclosporine, causing a significant increase in its concentration (up to 50 times the normal maximum concentration), leading to elevated toxicity.
Antacids/Sucralfate (e.g., Aluminum/Magnesium Hydroxide) Reduces the overall availability of this medication in the body. A minimum of two hours of spacing between doses is required.
Narcotic Analgesics (e.g., Tramadol) & Anticholinergics May antagonize the medication's prokinetic (gastrointestinal motility enhancing) action. Use with extreme caution.
Antidepressants (e.g., Fluoxetine, Sertraline) Certain Selective Serotonin Reuptake Inhibitors (SSRIs) are explicitly contraindicated or advised against due to increased side-effect risk.
Antihypertensive Agents (e.g., Diltiazem) Use with caution is necessary, as there is an increased risk of adverse effects.

Alcohol (Ethanol) consumption should be limited or avoided while taking this medicine as it can heighten the risk of adverse effects, including excessive drowsiness and central nervous system depression.

Mechanism of Action

Enhanced Central Inhibitory Signaling

Cyra LS functions as a positive allosteric modulator (PAM), primarily targeting the Glycine receptor (GlyR) and the GABA-A receptor (GABAAR) in the central nervous system (CNS). By binding to specific sites on these receptors, it increases the influx of chloride ions (Cl^-) into the postsynaptic neuron. This action amplifies the natural inhibitory effects of GABA and glycine, hyperpolarizing the cell membrane and reducing neuronal excitability.

Modulation of Spinal Motor and Nociceptive Pathways

The enhanced inhibitory signaling is targeted at the spinal cord and brainstem, systems responsible for regulating motor output and ascending sensory transmission. Increased inhibition suppresses the firing of interneurons and alpha motor neurons involved in generating exaggerated muscle responses. This mechanism results in the modulation of muscle hypertonia and exaggerated stretch reflexes. Furthermore, the inhibition dampens central nociceptive signal transmission, affecting the overall excitability in both motor and sensory systems.

Dosage and Administration Information

Instruction Map: How to use Cyra LS — Administration Guidelines

The following details the administration guidelines for Cyra LS (a combination of rabeprazole and levosulpiride). The medication must be taken exactly as prescribed by a healthcare provider.

Administration Scope

Classification Rule
Route of Administration Oral
Dosing Schedule Typically once daily, or as determined by a physician.
Timing in Relation to Meals Take on an empty stomach approximately 30 to 60 minutes before a meal, preferably in the morning.
Preparation Requirements The capsule/tablet must be swallowed whole; it must not be crushed, chewed, or opened.
Age-Group Rules Not generally recommended for use in children and adolescents (under 18 years of age). Dose reduction may be appropriate in elderly patients.
Missed-Dose Rules If a dose is missed, take it as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed one. Do not double the dose to compensate.

Resulting Procedural Structure

Step Sequence:

  • Swallow the capsule or tablet whole with a glass of water.
  • Do not break, chew, or crush the medication.
  • Take one dose daily, as instructed by your doctor.
  • Ensure the dose is taken on an empty stomach, before your morning meal.

This medication is a combination product administered orally, typically on a daily schedule. The specific procedural instructions emphasize the integrity of the capsule's delayed-release formulation by requiring it to be swallowed whole and consumed pre-meal, a timing crucial for the drug's intended action.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether Cyra LS (a combination of rabeprazole and levosulpiride) might affect symptoms associated with conditions such as Gastroesophageal Reflux Disease (GERD) and irritable bowel syndrome. Studies investigated potential changes in symptoms across a variety of clinical settings.

In placebo-controlled trials, studies reported improvements in daily functioning for some participants. Research examined whether the drug affected specific biological markers related to gut motility and acid suppression.

One large-scale trial compared Cyra LS to other therapies, reporting different side-effect profiles. This study focused on comparing reported adverse events between the treatment groups. Further comparison studies are ongoing.

Study Protocols and Administration

Study protocols evaluated the use of the combination at the onset of symptoms for conditions like GERD. Dosing regimens varied across different research studies, with the majority focusing on a single daily dose of 20 mg of rabeprazole combined with 75 mg of levosulpiride.

Studies investigated both short-term (typically 4 weeks) and longer-term (up to 6 months) administration of the drug. Longer trials explored the need for dosage adjustment over time, particularly for the rabeprazole component.

Safety and Tolerability Profiles

The most commonly reported side effects in clinical trials included mild nausea, headache, dizziness, and gastrointestinal symptoms like diarrhea or flatulence. These events were generally transient in nature, and study records noted the frequency of participant discontinuation.

Study participants were observed for rare but serious side effects, such as allergic reactions, liver enzyme elevation, or neurological symptoms associated with the levosulpiride component. Research protocols often excluded participants with a history of severe liver or kidney issues.

While some studies found limited evidence for certain specific claims, further research continues to evaluate Cyra LS in managing acid-related gastrointestinal conditions.

Key Studies & References

  1. Levosulpiride: An Old Drug with New Applications in Gastrointestinal Disorders

Frequently Asked Questions (FAQ)

Common questions about Cyra LS (FAQ)

Q: How quickly should I expect Cyra LS to start working for my symptoms?

Studies show that the acid-reducing component of Cyra LS begins working within one hour after it's taken. Significant effects on gastric acidity are typically noted after one day, and the maximum acid-blocking effect is generally reached after seven days of consistent dosing, based on clinical studies.

Q: Is Cyra LS something I need to take long-term?

Official information indicates that treatment with this medicine is often intended for a short duration, typically 4 to 8 weeks, for healing conditions like erosive reflux disease. While long-term use is sometimes prescribed, the length of treatment is assessed on a case-by-case basis.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Cyra LS?

Because this medicine significantly reduces stomach acid, it may interfere with the absorption of some substances, such as iron salts. Long-term use is also associated with regulatory notes regarding a potential for Vitamin B12 deficiency.

Q: What time of day is best to take Cyra LS for maximum effect?

Regulatory guidelines suggest taking this medication once daily, on an empty stomach, approximately 30 to 60 minutes before a meal. Official information indicates the dose is typically scheduled for the morning.

Q: Does taking Cyra LS long-term increase the risk of any other health problems?

Official safety information notes that using the acid-reducing component for one year or longer may be associated with an increased risk of bone fractures, particularly in the hip, wrist, or spine. There is also a potential risk of Vitamin B12 deficiency with prolonged use.

Q: What happens if I stop taking Cyra LS suddenly?

Official data indicates that when the acid-reducing component is stopped, the body’s natural production of stomach acid typically returns to normal levels over a period of about one to two weeks. Stopping treatment early may lead to the recurrence or worsening of symptoms.

Q: Does Cyra LS cause weight gain or weight loss in some people?

Official safety data lists weight gain as a possible side effect associated with both active components of the medicine. This effect is based on documented side effects reported in clinical trials.

Q: Can Cyra LS affect my sleep patterns?

Yes, official product information lists sleep-related side effects. Insomnia (difficulty sleeping) is a common side effect of one component, and drowsiness is listed as an uncommon reaction.

Q: Does Cyra LS lose its effectiveness over time?

Regulatory studies show that the medicine's acid-blocking effect actually increases slightly over the first few days of use, achieving steady-state inhibition after approximately three days. Tolerance (a loss of effectiveness) is not explicitly listed as an effect in official documents.

Q: Are the side effects of Cyra LS different for men versus women?

Yes, the official side effect profile notes differences based on sex. Reactions associated with the levosulpiride component, such as menstrual disorders (irregular periods) and galactorrhea (abnormal milk production), are unique to female patients.

Q: Is it true that Cyra LS can sometimes cause joint pain?

Official information lists myalgia (muscle pain) as an uncommon side effect. Additionally, the drug class is associated with an increased risk of bone fracture with long-term use, which may involve joint areas.

Q: What evidence supports the use of Cyra LS for stomach ulcers?

The rabeprazole component of this medicine is specifically indicated in official documents for the healing of duodenal ulcers. It is also used as part of a multi-drug regimen for the treatment of Helicobacter pylori infection, a common cause of ulcers.

Q: Is Cyra LS used to treat H. pylori infection?

Yes, official guidance states that the rabeprazole component is used as part of a combination regimen (three-drug therapy) to eradicate the bacteria Helicobacter pylori. This is done to reduce the risk of recurring duodenal ulcers.

Q: Are there known issues with taking Cyra LS before surgery?

The rabeprazole component of the medicine can significantly reduce the volume and acidity of gastric contents before a procedure. The effect of reducing the volume and acidity of gastric contents is a known factor that may be relevant to aspiration risk during a procedure.

Q: Do children ever take Cyra LS, and if so, for what?

The full combination medicine is not generally recommended for use in children and adolescents under 18 years old. However, the rabeprazole component alone has established dosage regimens for treating GERD (reflux disease) in some pediatric patients.

Q: Does Cyra LS have a strong withdrawal effect?

While the regulatory information notes that acid secretion activity returns to normal levels gradually over one to two weeks after discontinuation, there are no specific warnings that describe 'strong withdrawal' in the sense of severe physical dependence.

Q: Can you take Cyra LS with an antacid for breakthrough symptoms?

Regulatory information indicates that antacids can reduce the overall absorption of this medicine. A minimum of two hours of spacing between the doses of this medicine and antacids is necessary to prevent the antacid from lowering the effectiveness of Cyra LS.

Q: How long does it take for the active ingredients of Cyra LS to leave the body?

The rabeprazole component has a short plasma half-life of approximately 1 to 2 hours. Metabolites of the medicine are mainly excreted via the kidneys.

How should Cyra LS be stored and disposed of?

How to Store and Dispose of Cyra LS

Adherence to official storage and disposal requirements is essential to maintain the integrity of Cyra LS (Levosulpiride and Rabeprazole).

Official Storage Conditions

The medicine must be stored at a temperature not exceeding 30 C or between 20 C and 25 C (room temperature). It is mandatory to protect the product from light and moisture and to keep the container tightly closed in its original packaging. The product must not be frozen. For safety, the medicine must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Cyra LS must be discarded according to the instructions on the package and local regulations for pharmaceutical waste. Disposal must be done in a way that prevents consumption by pets or other people.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cyra LS found in:

A-Z Index: